Possible involvement of the antiserotoninergic and antihistaminergic activity in the anticataleptogenic effect of EGYT-2509.
István
G
G
EGIS Pharmaceuticals, Division of Pharmacology, Budapest.
Gyertyán
I
I
Gigler
G
G
Somogyi
E
E
Petöcz
L
L
D000818:Animals; D014150:Antipsychotic Agents / Q000037:antagonists & inhibitors; D002375:Catalepsy / Q000139:chemically induced / Q000517:prevention & control*; D003989:Dibenzoxazepines / Q000494:pharmacology*; D006633:Histamine Antagonists; D010095:Oxotremorine / Q000037:antagonists & inhibitors; D051381:Rats; D012702:Serotonin Antagonists; D014202:Tremor / Q000139:chemically induced / Q000517:prevention & control
D014150:Antipsychotic Agents; D003989:Dibenzoxazepines; D006633:Histamine Antagonists; D012702:Serotonin Antagonists; D010095:Oxotremorine; C049176:EGYT 2509